Agios Pharmaceuticals, Inc. Stock Performance
as on January 10, 2026 at 2:29 am IST
Day's Low
Day's High
$28.02$28.7
1.34%
Downside
1.06%
Upside
52 Week's Low
52 Week's High
$22.24$4621.69%
Downside
61.97%
Upside
Agios Pharmaceuticals, Inc. share price movements today
- Previous Close
- $28.16
- Open
- $28.55
- Volume
- 1.2M
- Day's Low - High
- $28.02 - $28.7
- 52 Week Low - High
- $22.24 - $46
Agios Pharmaceuticals, Inc. Historical Returns
- 1 Month Return
- + 4.88 %
- 3 Month Return
- -33.63 %
- 1 Year Return
- -21.56 %
- 3 Year Return
- -3.63 %
- 5 Year Return
- -38.56 %
Agios Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Check Agios Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.7B
EPS (TTM)
-7.02
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
1.63
Industry PE ratio
7.391222222222222
PEG Ratio
0EBITDA
-470.3M
Revenue (TTM)
44.8M
Profit Margin
0.00%
Return On Equity TTM
-27.57%
Agios Pharmaceuticals, Inc. Stock Valuation
Track how Agios Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Agios Pharmaceuticals, Inc. in the last 5 years
Lowest (-7.40x)
December 31, 2024
Today (1.63x)
January 9, 2026
Industry (7.39x)
January 9, 2026
Highest (2.47x)
June 30, 2021
Today’s Price to Earnings Ratio: 1.63x
Agios Pharmaceuticals, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Agios Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.7B | -38.56% | 1.63 | 0.00% | |
| BUY | $55.8B | 172.33% | 1408.33 | 1.36% | |
| BUY | $124.1B | 98.18% | 34.02 | 31.35% | |
| NA | $36.9B | NA | 629.94 | 1.38% | |
| BUY | $86.1B | 60.61% | 19.46 | 32.13% |
Stock Returns calculator for Agios Pharmaceuticals, Inc. Stock including INR - Dollar returns
The Agios Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Agios Pharmaceuticals, Inc. investment value today
Current value as on today
₹84,025
Returns
Returns from Agios Pharmaceuticals, Inc. Stock
Dollar Returns*
₹4,916 (+4.92%)
Analyst Recommendation on Agios Pharmaceuticals, Inc. Stock
Based on 15 analysts
73.33%
Buy
26.67%
Hold
0.00%
Sell
Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for Agios Pharmaceuticals, Inc.. Average target price of $36.75
Agios Pharmaceuticals, Inc. Share Price Target
Get share price movements and forecasts by analysts on Agios Pharmaceuticals, Inc..
What analysts predicted
22.72%UPSIDE
Target Price
$36.75
Current Price
$28.4
Analyzed by
15 Analysts
Target
$36.75
Agios Pharmaceuticals, Inc. target price $36.75, a slight upside of 22.72% compared to current price of $28.4. According to 15 analysts rating.
Agios Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest
Search interest for Agios Pharmaceuticals, Inc. Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Agios Pharmaceuticals, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Agios Pharmaceuticals, Inc. Annual Profit & Loss
All numbers in Millions USD
Agios Pharmaceuticals, Inc. Quarterly Cash Flow
All numbers in Millions USD
Agios Pharmaceuticals, Inc. Annual Cash Flow
All numbers in Millions USD
Agios Pharmaceuticals, Inc. News & Key Events
Today's Timeline - 24 December
Wed, 10:37 AM
-Agios Pharmaceuticals announces FDA approval for AQVESME (mitapivat) for anemia in thalassemia, shares fell 1.4% to $24.59.
Wed, 06:01 PM
-Agios shares rise 9.80% to $27.00 premarket after FDA approval of AQVESME for thalassemia-related anemia.
Wed, 06:48 PM
-FDA expands approval for mitapivat, expected to generate $320 million additional peak revenue opportunity.
Today's Timeline - 24 December
Wed, 10:33 PM
-Management outlines marketing plans for AQVESME, targeting 4,000 patients with a price of $425,000 annually.
Insights on Agios Pharmaceuticals, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, -112.02M → -103.43M (in $), with an average increase of 8.3% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 8.72M → 12.88M (in $), with an average increase of 16.6% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Beone Medicines Ltd has given 81.3% return, outperforming this stock by 99.5%
- NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 28.1% return, outperforming this stock by 32.9%
NEGATIVE IMPACTPrice Dip
In the last 3 months, AGIO stock has moved down by -30.7%
About Agios Pharmaceuticals, Inc.
| Organisation | Agios Pharmaceuticals, Inc. |
| Headquarters | 88 Sidney Street, Cambridge, MA, United States, 02139 |
| Industry | Health Technology |
| CEO | Mr. Brian M. Goff M.B.A. |
| E-voting on shares | Click here to vote |
Key Management of Agios Pharmaceuticals, Inc.
Name | Title |
|---|---|
Dr. Craig B. Thompson M.D. | Co-Founder |
Dr. Shin-San Su Ph.D. | Co-Founder |
Mr. Brian M. Goff M.B.A. | CEO & Director |
Ms. Cecilia Jones | Chief Financial Officer |
Mr. James William Burns | Corporate Secretary & Chief Legal Officer |
Dr. Lewis clayton Cantley Ph.D. | Co-Founder |
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder |
Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
Ms. Tsveta Milanova | Chief Commercial Officer |
Mr. T. J. Washburn | VP, Controller & Principal Accounting Officer |
FAQs
What is Agios Pharmaceuticals, Inc. share price today?
Agios Pharmaceuticals, Inc. share price today is $28.4 as on at the close of the market. Agios Pharmaceuticals, Inc. share today touched a day high of $28.7 and a low of $28.02.
What is the 52 week high and 52 week low for Agios Pharmaceuticals, Inc. share?
Agios Pharmaceuticals, Inc. share touched a 52 week high of $46 on and a 52 week low of $22.24 on . Agios Pharmaceuticals, Inc. stock price today i.e. is closed at $28.4,which is 38.26% down from its 52 week high and 27.70% up from its 52 week low.
What is Agios Pharmaceuticals, Inc.'s market capitalisation today?
Agios Pharmaceuticals, Inc. market capitalisation is $0.00T as on .
How to invest in Agios Pharmaceuticals, Inc. Stock (AGIO) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Agios Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agios Pharmaceuticals, Inc. Shares that will get you 0.0528 shares as per Agios Pharmaceuticals, Inc. share price of $28.4 per share as on January 10, 2026 at 2:29 am IST.
What is the minimum amount required to buy Agios Pharmaceuticals, Inc. Stock (AGIO) from India?
Indian investors can start investing in Agios Pharmaceuticals, Inc. (AGIO) shares with as little as ₹90.123 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹901.23 in Agios Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Agios Pharmaceuticals, Inc. share’s latest price of $28.4 as on January 10, 2026 at 2:29 am IST, you will get 0.3521 shares of Agios Pharmaceuticals, Inc.. Learn more about
fractional shares .
What are the returns that Agios Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?
Agios Pharmaceuticals, Inc. stock has given -38.56% share price returns and 22.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?